Capital International Investors Allogene Therapeutics, Inc. Transaction History

Capital International Investors

$504 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $10.1 Million - $17 Million	982,767 Added 22.71%	5,310,109 $57.3 Million
Q2 2022 Aug 15, 2022	BUY	$6.78 - $12.28 $25.4 Million - $45.9 Million	3,740,264 Added 637.1%	4,327,342 $49.3 Million
Q1 2022 May 16, 2022	SELL	$7.65 - $15.29 $7.59 Million - $15.2 Million	-992,031 Reduced 62.82%	587,078 $5.35 Million
Q4 2021 Feb 14, 2022	SELL	$13.13 - $24.52 $25.7 Million - $47.9 Million	-1,955,278 Reduced 55.32%	1,579,109 $23.6 Million
Q3 2021 Nov 15, 2021	BUY	$21.01 - $27.64 $194,825 - $256,305	9,273 Added 0.26%	3,534,387 $90.8 Million
Q2 2021 Aug 16, 2021	SELL	$23.49 - $35.8 $72.2 Million - $110 Million	-3,073,922 Reduced 46.58%	3,525,114 $91.9 Million
Q1 2021 May 14, 2021	SELL	$25.79 - $39.02 $13.6 Million - $20.6 Million	-529,183 Reduced 7.42%	6,599,036 $233 Million
Q4 2020 Feb 12, 2021	SELL	$25.24 - $43.45 $3.44 Million - $5.92 Million	-136,170 Reduced 1.87%	7,128,219 $180 Million
Q3 2020 Nov 13, 2020	BUY	$32.38 - $44.96 $1.6 Million - $2.22 Million	49,476 Added 0.69%	7,264,389 $274 Million
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $48.5 Million - $142 Million	2,636,113 Added 57.57%	7,214,913 $309 Million
Q1 2020 May 15, 2020	BUY	$18.22 - $28.25 $12.6 Million - $19.5 Million	690,779 Added 17.77%	4,578,800 $89 Million
Q4 2019 Feb 18, 2020	SELL	$24.82 - $31.4 $1.3 Million - $1.65 Million	-52,538 Reduced 1.33%	3,888,021 $101 Million
Q3 2019 Nov 14, 2019	BUY	$26.11 - $32.99 $443 - $560	17 Added 0.0%	3,940,559 $107 Million
Q2 2019 Aug 14, 2019	BUY	$25.56 - $31.09 $48.8 Million - $59.4 Million	1,908,988 Added 93.97%	3,940,542 $106 Million
Q4 2018 Feb 14, 2019	BUY	$22.5 - $33.3 $45.7 Million - $67.7 Million	2,031,554 New	2,031,554 $54.7 Million

Others Institutions Holding ALLO

# of Institutions

165

Shares Held

134M

Call Options Held

59.4K

Put Options Held

113K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $279M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.

Account